12.81
-0.49(-3.68%)
Currency In NaN
| Previous Close | 13.3 |
| Open | 13.17 |
| Day High | 13.35 |
| Day Low | 12.32 |
| 52-Week High | 19.58 |
| 52-Week Low | 4.88 |
| Volume | 169,228 |
| Average Volume | 137,575 |
| Market Cap | 277.96M |
| PE | -7.58 |
| EPS | -1.69 |
| Moving Average 50 Days | 11.53 |
| Moving Average 200 Days | 11.23 |
| Change | -0.49 |
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
GlobeNewswire Inc.
Oct 08, 2025 12:00 PM GMT
Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient PopulationSAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on develop
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
GlobeNewswire Inc.
Sep 23, 2025 8:05 PM GMT
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today